{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:03:20Z","timestamp":1792029800642,"version":"4.4.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:00:00Z","timestamp":1608076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:00:00Z","timestamp":1608076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Renin\u2013angiotensin system inhibitors are recommended for treating hypertension with chronic kidney disease. The addition of a mineralocorticoid receptor blocker may be one option to achieve target blood pressure. We investigated the efficacy and safety of esaxerenone, a mineralocorticoid receptor blocker, in Japanese hypertensive patients with moderate kidney dysfunction. Two multicenter, open-label, nonrandomized dose escalation studies were conducted to investigate esaxerenone monotherapy and add-on therapy to renin\u2013angiotensin system inhibitor treatment. Esaxerenone therapy was initiated at 1.25\u2009mg\/day and titrated to 2.5 and then 5\u2009mg\/day for a treatment duration of 12 weeks. Primary endpoints were changes from baseline in sitting systolic and diastolic blood pressure. Safety, pharmacokinetics, and urinary albumin-to-creatinine ratios were also assessed. Thirty-three patients received monotherapy, and 58 received add-on therapy; the mean baseline estimated glomerular filtration rates were 51.9 and 50.9\u2009mL\/min\/1.73\u2009m<jats:sup>2<\/jats:sup>, respectively. The esaxerenone dosage was increased to \u22652.5\u2009mg\/day in 100% (<jats:italic>n<\/jats:italic>\u2009=\u200933) and 93.1% (<jats:italic>n<\/jats:italic>\u2009=\u200954) of patients receiving monotherapy and add-on therapy, respectively. Reductions in sitting blood pressure from baseline to the end of treatment were similar (monotherapy: \u221218.5\/\u22128.8\u2009mmHg; add-on therapy: \u221217.8\/\u22128.1\u2009mmHg; both <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). The antihypertensive effects of esaxerenone were consistent across patient subgroups. A serum K<jats:sup>+<\/jats:sup> level \u22655.5\u2009mEq\/L was observed in seven patients (12.1%) receiving add-on therapy but in none receiving monotherapy. All increases in serum K<jats:sup>+<\/jats:sup> levels were transient, and no patient met predefined serum K<jats:sup>+<\/jats:sup> level criteria for dose reduction or therapy discontinuation. No patient discontinued treatment owing to kidney function decline. Esaxerenone was effective and well tolerated in hypertensive patients with moderate kidney dysfunction.<\/jats:p>","DOI":"10.1038\/s41440-020-00585-y","type":"journal-article","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T03:02:24Z","timestamp":1608087744000},"page":"489-497","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction"],"prefix":"10.1038","volume":"44","author":[{"given":"Sadayoshi","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Rakugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Setsuko","family":"Iijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,16]]},"reference":[{"key":"585_CR1","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","volume":"382","author":"RT Gansevoort","year":"2013","unstructured":"Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382:339\u201352.","journal-title":"Lancet"},{"key":"585_CR2","volume-title":"Global Status Report on Noncommunicable Diseases 2010","author":"World Health Organization.","year":"2011","unstructured":"World Health Organization. Global Status Report on Noncommunicable Diseases 2010. Geneva, Switzerland: World Health Organization; 2011."},{"key":"585_CR3","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.2215\/CJN.07370714","volume":"10","author":"EK Chowdhury","year":"2015","unstructured":"Chowdhury EK, Langham RG, Ademi Z, Owen A, Krum H, Wing LM, et al. Rate of change in renal function and mortality in elderly treated hypertensive patients. Clin J Am Soc Nephrol. 2015;10:1154\u201361.","journal-title":"Clin J Am Soc Nephrol"},{"key":"585_CR4","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1093\/ajh\/hpv003","volume":"28","author":"A Hirayama","year":"2015","unstructured":"Hirayama A, Konta T, Kamei K, Suzuki K, Ichikawa K, Fujimoto S, et al. Blood pressure, proteinuria, and renal function decline: associations in a large community-based population. Am J Hypertens. 2015;28:1150\u20136.","journal-title":"Am J Hypertens"},{"key":"585_CR5","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/ki.1984.229","volume":"26","author":"RD Lindeman","year":"1984","unstructured":"Lindeman RD, Tobin JD, Shock NW. Association between blood pressure and the rate of decline in renal function with age. Kidney Int. 1984;26:861\u20138.","journal-title":"Kidney Int"},{"key":"585_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/sj.ki.5002017","volume":"71","author":"K Yamagata","year":"2007","unstructured":"Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int. 2007;71:159\u201366.","journal-title":"Kidney Int"},{"key":"585_CR7","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/hr.2013.80","volume":"37","author":"K Shimamoto","year":"2014","unstructured":"Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res. 2014;37:253\u2013390.","journal-title":"Hypertens Res"},{"key":"585_CR8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2147\/IBPC.S13783","volume":"6","author":"JW Funder","year":"2013","unstructured":"Funder JW. Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine. Integr Blood Press Control. 2013;6:129\u201338.","journal-title":"Integr Blood Press Control"},{"key":"585_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/FJC.0000000000000329","volume":"67","author":"EP Gomez-Sanchez","year":"2016","unstructured":"Gomez-Sanchez EP. Third-generation mineralocorticoid receptor antagonists: why do we need a fourth? J Cardiovasc Pharm. 2016;67:26\u201338.","journal-title":"J Cardiovasc Pharm"},{"key":"585_CR10","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.pharmthera.2015.07.006","volume":"154","author":"J Deinum","year":"2015","unstructured":"Deinum J, Riksen NP, Lenders JW. Pharmacological treatment of aldosterone excess. Pharm Ther. 2015;154:120\u201333.","journal-title":"Pharm Ther"},{"key":"585_CR11","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.amjmed.2016.01.039","volume":"129","author":"M Epstein","year":"2016","unstructured":"Epstein M, Duprez DA. Resistant hypertension and the pivotal role for mineralocorticoid receptor antagonists: a clinical update 2016. Am J Med. 2016;129:661\u20136.","journal-title":"Am J Med"},{"key":"585_CR12","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/jhh.2015.119","volume":"30","author":"S Takahashi","year":"2016","unstructured":"Takahashi S, Katada J, Daida H, Kitamura F, Yokoyama K. Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: a systematic review and meta-analysis. J Hum Hypertens. 2016;30:534\u201342.","journal-title":"J Hum Hypertens"},{"key":"585_CR13","unstructured":"Aldactone\u00ae (spironolactone) US prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/012151s062lbl.pdf. Accessed 9 October 2018."},{"key":"585_CR14","unstructured":"INSPRA\u00ae (eplerenone) US prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2002\/21437lbl.pdf. Accessed 9 October 2018."},{"key":"585_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","volume":"200","author":"M Lainscak","year":"2015","unstructured":"Lainscak M, Pelliccia F, Rosano G, Vitale C, Schiariti M, Greco C, et al. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone. Int J Cardiol. 2015;200:25\u20139.","journal-title":"Int J Cardiol"},{"key":"585_CR16","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ijcard.2014.09.091","volume":"177","author":"F Pelliccia","year":"2014","unstructured":"Pelliccia F, Patti G, Rosano G, Greco C, Gaudio C. Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension: systematic review and meta-analysis. Int J Cardiol. 2014;177:219\u201328.","journal-title":"Int J Cardiol"},{"key":"585_CR17","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ejphar.2015.06.015","volume":"761","author":"K Arai","year":"2015","unstructured":"Arai K, Homma T, Morikawa Y, Ubukata N, Tsuruoka H, Aoki K, et al. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. Eur J Pharm. 2015;761:226\u201334.","journal-title":"Eur J Pharm"},{"key":"585_CR18","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1124\/dmd.118.084897","volume":"47","author":"M Yamada","year":"2019","unstructured":"Yamada M, Mendell J, Takakusa H, Shimizu T, Ando O. Pharmacokinetics, metabolism, and excretion of [14C]esaxerenone, a novel mineralocorticoid receptor blocker in humans. Drug Metab Dispos. 2019;47:340\u20139.","journal-title":"Drug Metab Dispos"},{"key":"585_CR19","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ejphar.2015.11.028","volume":"769","author":"K Arai","year":"2015","unstructured":"Arai K, Tsuruoka H, Homma T. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats. Eur J Pharm. 2015;769:266\u201373.","journal-title":"Eur J Pharm"},{"key":"585_CR20","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41440-018-0187-1","volume":"42","author":"L Li","year":"2019","unstructured":"Li L, Guan Y, Kobori H, Morishita A, Kobara H, Masaki T, et al. Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats. Hypertens Res. 2019;42:769\u201378.","journal-title":"Hypertens Res"},{"key":"585_CR21","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/s41440-019-0211-0","volume":"42","author":"AS Bhuiyan","year":"2019","unstructured":"Bhuiyan AS, Rafiq K, Kobara H, Masaki T, Nakano D, Nishiyama A. Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice. Hypertens Res. 2019;42:892\u2013902.","journal-title":"Hypertens Res"},{"key":"585_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","volume":"75","author":"S Ito","year":"2020","unstructured":"Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M, Yamakawa S. Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN Study). Hypertension. 2020;75:51\u20138.","journal-title":"Hypertension"},{"key":"585_CR23","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1038\/s41440-019-0314-7","volume":"42","author":"H Rakugi","year":"2019","unstructured":"Rakugi H, Ito S, Itoh H, Okuda Y, Yamakawa S. Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension. Hypertens Res. 2019;42:1932\u201341.","journal-title":"Hypertens Res"},{"key":"585_CR24","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1038\/s41440-019-0270-2","volume":"42","author":"H Itoh","year":"2019","unstructured":"Itoh H, Ito S, Rakugi H, Okuda Y, Nishioka S. Efficacy and safety of dose-escalation of low-dose esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study. Hypertens Res. 2019;42:1572\u201381.","journal-title":"Hypertens Res"},{"key":"585_CR25","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.2215\/CJN.14751218","volume":"148","author":"S Ito","year":"2019","unstructured":"Ito S, Shikata K, Nangaku M, Okuda Y, Sawanobori T. Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria: a randomized, double-blind, placebo-controlled, phase II trial. Clin J Am Soc Nephrol. 2019;148:1161\u201372.","journal-title":"Clin J Am Soc Nephrol"},{"key":"585_CR26","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jash.2010.09.006","volume":"4","author":"J Heshka","year":"2010","unstructured":"Heshka J, Ruzicka M, Hiremath S, McCormick BB. Spironolactone for difficult to control hypertension in chronic kidney disease: an analysis of safety and efficacy. J Am Soc Hypertens. 2010;4:295\u2013301.","journal-title":"J Am Soc Hypertens"},{"key":"585_CR27","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/jhh.2011.60","volume":"26","author":"R Pisoni","year":"2012","unstructured":"Pisoni R, Acelajado MC, Cartmill FR, Dudenbostel T, Dell\u2019Italia LJ, Cofield SS, et al. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease. J Hum Hypertens. 2012;26:502\u20136.","journal-title":"J Hum Hypertens"},{"key":"585_CR28","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12882-016-0337-0","volume":"17","author":"G Currie","year":"2016","unstructured":"Currie G, Taylor AH, Fujita T, Ohtsu H, Lindhardt M, Rossing P, et al. Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol. 2016;17:127.","journal-title":"BMC Nephrol"},{"key":"585_CR29","doi-asserted-by":"publisher","first-page":"810","DOI":"10.3109\/0886022X.2012.672156","volume":"34","author":"TK Ma","year":"2012","unstructured":"Ma TK, Szeto CC. Mineralocorticoid receptor antagonist for renal protection. Ren Fail. 2012;34:810\u20137.","journal-title":"Ren Fail"},{"key":"585_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/HJH.0b013e3283599b6a","volume":"31","author":"G Colussi","year":"2013","unstructured":"Colussi G, Catena C, Sechi LA. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension. J Hypertens. 2013;31:3\u201315.","journal-title":"J Hypertens"},{"key":"585_CR31","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/hr.2012.182","volume":"36","author":"A Sato","year":"2013","unstructured":"Sato A. Mineralocorticoid receptor antagonists: their use and differentiation in Japan. Hypertens Res. 2013;36:185\u201390.","journal-title":"Hypertens Res"},{"key":"585_CR32","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1365-2125.2011.04102.x","volume":"73","author":"NC Edwards","year":"2012","unstructured":"Edwards NC, Steeds RP, Chue CD, Stewart PM, Ferro CJ, Townend JN. The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. Br J Clin Pharm. 2012;73:447\u201354.","journal-title":"Br J Clin Pharm"},{"key":"585_CR33","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","volume":"70","author":"S Bianchi","year":"2006","unstructured":"Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006;70:2116\u201323.","journal-title":"Kidney Int"},{"key":"585_CR34","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1038\/s41440-019-0320-9","volume":"42","author":"A Sato","year":"2019","unstructured":"Sato A. Does the temporary decrease in the estimated glomerular filtration rate (eGFR) after initiation of mineralocorticoid receptor (MR) antagonist treatment lead to a long-term renal protective effect? Hypertens Res. 2019;42:1841\u20137.","journal-title":"Hypertens Res"},{"key":"585_CR35","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1210\/jc.2003-032149","volume":"89","author":"DG Levy","year":"2004","unstructured":"Levy DG, Rocha R, Funder JW. Distinguishing the antihypertensive and electrolyte effects of eplerenone. J Clin Endocrinol Metab. 2004;89:2736\u201340.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41440-020-00585-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41440-020-00585-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41440-020-00585-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:23:07Z","timestamp":1684617787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-020-00585-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,16]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["585"],"URL":"https:\/\/doi.org\/10.1038\/s41440-020-00585-y","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,16]]},"assertion":[{"value":"12 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SI, HR, and HI have received lecture fees and research funding from Daiichi Sankyo Co., Ltd. YO and SI are employees of Daiichi Sankyo Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}